Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibalizumab dose-response study in treatment-experienced HIV-1
NCT00784147Phase 2Completed
- Sponsor
- TaiMed Biologics
- Start
- Aug 2008
- Primary completion
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ibalizumab in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by TaiMed Biologics. Primary endpoint: Proportion of Patients Achieving Undetectable Viral Loads at 24 weeks. Started Aug 2008; status: completed.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00784147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784147.